tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jan 21;10(2):160.
doi: 10.3390/vaccines10020160.
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
Ka-Wa Khong[SUP] 1 [/SUP], Danlei Liu[SUP] 1 [/SUP], Ka-Yi Leung[SUP] 2 [/SUP], Lu Lu[SUP] 2 [/SUP], Hoi-Yan Lam[SUP] 2 [/SUP], Linlei Chen[SUP] 2 [/SUP], Pui-Chun Chan[SUP] 2 [/SUP], Ho-Ming Lam[SUP] 1 [/SUP], Xiaochun Xie[SUP] 1 [/SUP], Ruiqi Zhang[SUP] 1 [/SUP], Yujing Fan[SUP] 1 [/SUP], Kelvin Kai-Wang To[SUP] 2 3 4 [/SUP], Honglin Chen[SUP] 2 3 4 [/SUP], Kwok-Yung Yuen[SUP] 2 3 4 [/SUP], Kwok-Hung Chan[SUP] 2 3 4 [/SUP], Ivan Fan-Ngai Hung[SUP] 1 3 4 [/SUP]
Affiliations
Abstract
By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses.
Keywords: COVID-19; omicron variant; vaccines.
. 2022 Jan 21;10(2):160.
doi: 10.3390/vaccines10020160.
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
Ka-Wa Khong[SUP] 1 [/SUP], Danlei Liu[SUP] 1 [/SUP], Ka-Yi Leung[SUP] 2 [/SUP], Lu Lu[SUP] 2 [/SUP], Hoi-Yan Lam[SUP] 2 [/SUP], Linlei Chen[SUP] 2 [/SUP], Pui-Chun Chan[SUP] 2 [/SUP], Ho-Ming Lam[SUP] 1 [/SUP], Xiaochun Xie[SUP] 1 [/SUP], Ruiqi Zhang[SUP] 1 [/SUP], Yujing Fan[SUP] 1 [/SUP], Kelvin Kai-Wang To[SUP] 2 3 4 [/SUP], Honglin Chen[SUP] 2 3 4 [/SUP], Kwok-Yung Yuen[SUP] 2 3 4 [/SUP], Kwok-Hung Chan[SUP] 2 3 4 [/SUP], Ivan Fan-Ngai Hung[SUP] 1 3 4 [/SUP]
Affiliations
- PMID: 35214619
- DOI: 10.3390/vaccines10020160
Abstract
By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses.
Keywords: COVID-19; omicron variant; vaccines.